The Rational Use of Medicines (RUM) in Coronavirus Disease 2019 (COVID-19)
Abstract
The rational use of medicines was and still is a global health priority. In light of the COVID-19 Pandemic, ensuring and practicing the RUM has become even more challenging. Certain interventions from the list of core polciies recommended by the World Health Organization (WHO) bear additional importance in imporving RUM principles in practice. These recommendations are visited in this editorial.
1. World Health Organization (WHO). Promoting rational use of medicines [Internet]. 2021. Available from: https://www.who.int/activities/promoting-rational-use-of-medicines
2. World Health Organization (WHO). Rational use of medicines: progress in implementing the WHO medicines strategy. Report by the Secretariat. [Internet]. 2006 May. Report No.: EB118/6. Available from: https://apps.who.int/gb/ebwha/pdf_files/EB118/B118_6-en.pdf
3. Dutta S. Rational Use of Medicines: A Review. WJPMR [Internet]. 2019;5(3):193–132. Available from: https://journals.indexcopernicus.com/search/article?articleId=2272439
4. Statista. Number of coronavirus (COVID-19) clinical trials for drugs and vaccines worldwide as of June 3, 2021 [Internet]. Health, Pharma & Medtech - Pharmaceutical Products and Market. 2021. Available from: https://www.statista.com/statistics/1119086/coronavirus-drug-trials-by-type-worldwide/
5. World Health Organization (WHO). Therapeutics and COVID-19: living guideline [Internet]. COVID-19: Clinical care. 2021 [cited 2021 Apr 1]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1
6. World Health Organization (WHO). Solidarity Therapeutics Trial produces conclusive evidence on the effectiveness of repurposed drugs for COVID-19 in record time [Internet]. 2020. Available from: https://www.who.int/news/item/15-10-2020-solidarity-therapeutics-trial-produces-conclusive-evidence-on-the-effectiveness-of-repurposed-drugs-for-covid-19-in-record-time
7. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med 2020;383(21):2041–52.
8. Macías J, Pinilla A, Lao-Dominguez FA, et al. High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment. Sci Rep 2020;10(1):20958.
9. Touafchia A, Bagheri H, Carrié D, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect 2021; DOI: https://doi.org/10.1016/j.cmi.2021.02.013
10. World Health Organization (WHO). COVID-19 Clinical management: living guidance [Internet]. COVID-19: Clinical care. 2021 [cited 2021 Apr 1]. Available from: https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19
11. World Health Organization (WHO). Promoting rational use of medicines: core components. WHO Policy Perspectives. [Internet]. 2002. Available from: https://apps.who.int/iris/bitstream/handle/10665/67438/WHO_EDM_2002.3.pdf
2. World Health Organization (WHO). Rational use of medicines: progress in implementing the WHO medicines strategy. Report by the Secretariat. [Internet]. 2006 May. Report No.: EB118/6. Available from: https://apps.who.int/gb/ebwha/pdf_files/EB118/B118_6-en.pdf
3. Dutta S. Rational Use of Medicines: A Review. WJPMR [Internet]. 2019;5(3):193–132. Available from: https://journals.indexcopernicus.com/search/article?articleId=2272439
4. Statista. Number of coronavirus (COVID-19) clinical trials for drugs and vaccines worldwide as of June 3, 2021 [Internet]. Health, Pharma & Medtech - Pharmaceutical Products and Market. 2021. Available from: https://www.statista.com/statistics/1119086/coronavirus-drug-trials-by-type-worldwide/
5. World Health Organization (WHO). Therapeutics and COVID-19: living guideline [Internet]. COVID-19: Clinical care. 2021 [cited 2021 Apr 1]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1
6. World Health Organization (WHO). Solidarity Therapeutics Trial produces conclusive evidence on the effectiveness of repurposed drugs for COVID-19 in record time [Internet]. 2020. Available from: https://www.who.int/news/item/15-10-2020-solidarity-therapeutics-trial-produces-conclusive-evidence-on-the-effectiveness-of-repurposed-drugs-for-covid-19-in-record-time
7. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med 2020;383(21):2041–52.
8. Macías J, Pinilla A, Lao-Dominguez FA, et al. High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment. Sci Rep 2020;10(1):20958.
9. Touafchia A, Bagheri H, Carrié D, et al. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clin Microbiol Infect 2021; DOI: https://doi.org/10.1016/j.cmi.2021.02.013
10. World Health Organization (WHO). COVID-19 Clinical management: living guidance [Internet]. COVID-19: Clinical care. 2021 [cited 2021 Apr 1]. Available from: https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19
11. World Health Organization (WHO). Promoting rational use of medicines: core components. WHO Policy Perspectives. [Internet]. 2002. Available from: https://apps.who.int/iris/bitstream/handle/10665/67438/WHO_EDM_2002.3.pdf
| Files | ||
| Issue | Vol 9, No 2 (Spring 2021) | |
| Section | Editorial | |
| DOI | https://doi.org/10.18502/jpc.v9i2.6606 | |
| Keywords | ||
| Rational Use of Medicines COVID-19 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Karimian Z. The Rational Use of Medicines (RUM) in Coronavirus Disease 2019 (COVID-19). J Pharm Care. 2021;9(2):52-54.
